NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Post time 1 hour(s) ago

journal：Journal of Clinical Oncology

Authors：Jean Bourhis; Anne Auperin; Christian Borel; Gautier Lefebvre; Severine Racadot; Lionnel Geoffrois; Xu Shan Sun; Esma Saada; Beatriz Cirauqui; Tomasz Rutkowski; Stephanie Henry; Anouchka Modesto; Alison Johnson; Benoit Calderon; Yoann Pointreau; Elisabeth Perez Ruiz; Joanna Kazmierska; Amanda Psyrri; Ricard Mesia; Yungan Tao;

Published date：2025-6-10

DOI：10.1200/jco.2025.43.17_suppl.lba2

PDF link：https://ascopubs.org/doi/pdfdire ... 25.43.17_suppl.LBA2

Article link：https://doi.org/10.1200/jco.2025.43.17_suppl.lba2

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 9 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.